{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:07Z","timestamp":1707524527679},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"DOI":"10.7759\/cureus.25083","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T17:14:53Z","timestamp":1652807693000},"source":"Crossref","is-referenced-by-count":1,"title":["Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Noor ul ain","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noreen","family":"Naguit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Jakkoju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadia","family":"Laeeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiba","family":"Reghefaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Yook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeba","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun HY","year":"2018","unstructured":"Sun HY, Huang YW, Huang WC, et al.. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb). 2018, 111:121-6. 10.1016\/j.tube.2018.05.013","journal-title":"Tuberculosis (Edinb)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie GJ","year":"2018","unstructured":"Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018, 55:244-52. 10.1016\/j.amepre.2018.04.030","journal-title":"Am J Prev Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling TR","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al.. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011, 365:2155-66. 10.1056\/NEJMoa1104875","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease C","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, et al.. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017, 17:265. 10.1186\/s12879-017-2377-x","journal-title":"BMC Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007545.pub2","article-title":"Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB","author":"Sharma SK","year":"2013","unstructured":"Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013, 10.1002\/14651858.CD007545.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05766-9","article-title":"An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study","volume":"21","author":"Surey J","year":"2021","unstructured":"Surey J, Stagg HR, Yates TA, et al.. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC Infect Dis. 2021, 21:10.1186\/s12879-021-05766-9","journal-title":"BMC Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7524-4","article-title":"Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis","volume":"19","author":"S\u00e9raphin MN","year":"2019","unstructured":"S\u00e9raphin MN, Hsu H, Chapman HJ, de Andrade Bezerra JL, Johnston L, Yang Y, Lauzardo M. Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. BMC Public Health. 2019, 19:10.1186\/s12889-019-7524-4","journal-title":"BMC Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02464-16","article-title":"Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in india","volume":"61","author":"Ramachandran G","year":"2017","unstructured":"Ramachandran G, Agibothu Kupparam HK, Vedhachalam C, et al.. Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in india. Antimicrob Agents Chemother. 2017, 61:10.1128\/AAC.02464-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0035","article-title":"Improved treatment completion with shorter treatment regimens for latent tuberculous infection","volume":"22","author":"Macaraig MM","year":"2018","unstructured":"Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018, 22:1344-9. 10.5588\/ijtld.18.0035","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9\u00a0months of isoniazid, 4\u00a0months of rifampin and 3\u00a0months of isoniazid and rifapentine","volume":"17","author":"McClintock AH","year":"2017","unstructured":"McClintock AH, Eastment M, McKinney CM, et al.. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9\u00a0months of isoniazid, 4\u00a0months of rifampin and 3\u00a0months of isoniazid and rifapentine. BMC Infect Dis. 2017, 17:10.1186\/s12879-017-2245-8","journal-title":"BMC Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies D","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, et al.. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018, 379:440-53. 10.1056\/NEJMoa1714283","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00395-2018","article-title":"3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review","volume":"52","author":"Assefa Y","year":"2018","unstructured":"Assefa Y, Assefa Y, Woldeyohannes S, Hamada Y, Getahun H. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. Eur Respir J. 2018, 52:10.1183\/13993003.00395-2018","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01128-2018","article-title":"Treatment of latent tuberculosis with 12\u2005weeks isoniazid\/rifapentine in clinical practice","volume":"53","author":"Fr\u00f6berg G","year":"2019","unstructured":"Fr\u00f6berg G, Jansson L, Bruchfeld J. Treatment of latent tuberculosis with 12\u2005weeks isoniazid\/rifapentine in clinical practice. Eur Respir J. 2019, 53:10.1183\/13993003.01128-2018","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213524","article-title":"Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness","volume":"14","author":"Nwana N","year":"2019","unstructured":"Nwana N, Marks SM, Lan E, Chang AH, Holcombe M, Morris SB. Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness. PLoS One. 2019, 14:10.1371\/journal.pone.0213524","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement","volume":"161","year":"2000","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000, 161.221-47. 10.1164\/ajrccm.161.supplement_3.ats600","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref17","article-title":"Guidelines on the Management of Latent Tuberculosis Infection","year":"2015","unstructured":"Guidelines on the Management of Latent Tuberculosis Infection. World Health Organization, Geneva, Switzerland; 2015."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.10","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai JW","year":"2016","unstructured":"Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016, 5:10.1038\/emi.2016.10","journal-title":"Emerg Microbes Infect"},{"key":"ref19","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","year":"2011","unstructured":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011, 60.1650-3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix725","article-title":"Management of latent tuberculosis infection among healthcare workers: 10-year experience at a single center","volume":"65","author":"Arguello Perez E","year":"2017","unstructured":"Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE. Management of latent tuberculosis infection among healthcare workers: 10-year experience at a single center. Clin Infect Dis. 2017, 65:2105-11. 10.1093\/cid\/cix725","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0039-2016","article-title":"Treatment of latent tuberculosis infection","volume":"5","author":"Haley CA","year":"2017","unstructured":"Haley CA. Treatment of latent tuberculosis infection. Microbiol Spectr. 2017, 5:10.1128\/microbiolspec.TNMI7-0039-2016","journal-title":"Microbiol Spectr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore EE","year":"2015","unstructured":"Bliven-Sizemore EE, Sterling TR, Shang N, et al.. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015, 19:1039-44. 10.5588\/ijtld.14.0829","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling TR","year":"2015","unstructured":"Sterling TR, Moro RN, Borisov AS, et al.. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015, 61:527-35. 10.1093\/cid\/civ323","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2018.05.003","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse\u00a0events","volume":"52","author":"Lin SY","year":"2019","unstructured":"Lin SY, Chiu YW, Lu PL, Hwang SJ, Chen TC, Hsieh MH, Chen YH. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse\u00a0events. J Microbiol Immunol Infect. 2019, 52:158-62. 10.1016\/j.jmii.2018.05.003","journal-title":"J Microbiol Immunol Infect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02180-2018","article-title":"New short regimens for latent tuberculosis treatment: safety first!","volume":"52","author":"Menzies D","year":"2018","unstructured":"Menzies D, Trajman A. New short regimens for latent tuberculosis treatment: safety first!. Eur Respir J. 2018, 52:10.1183\/13993003.02180-2018","journal-title":"Eur Respir J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials","volume":"15","author":"Moro RN","year":"2018","unstructured":"Moro RN, Scott NA, Vernon A, et al.. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials. Ann Am Thorac Soc. 2018, 15:570-80. 10.1513\/AnnalsATS.201704-326OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino ME","year":"2015","unstructured":"Villarino ME, Scott NA, Weis SE, et al.. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015, 169:247-55. 10.1001\/jamapediatrics.2014.3158","journal-title":"JAMA Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children","volume":"379","author":"Diallo T","year":"2018","unstructured":"Diallo T, Adjobimey M, Ruslami R, et al.. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018, 379:454-63. 10.1056\/NEJMoa1714284","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1078345811435973","article-title":"Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence","volume":"18","author":"White MC","year":"2012","unstructured":"White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012, 18:131-42. 10.1177\/1078345811435973","journal-title":"J Correct Health Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3477-19","article-title":"Use of rifampin compared with isoniazid for the treatment of latent tuberculosis infection in Japan: a Bayesian inference with Markov Chain Monte Carlo method","volume":"59","author":"Iwata K","year":"2020","unstructured":"Iwata K, Morishita N, Nishiwaki M, Miyakoshi C. Use of rifampin compared with isoniazid for the treatment of latent tuberculosis infection in Japan: a Bayesian inference with Markov Chain Monte Carlo method. Intern Med. 2020, 59:2687-91. 10.2169\/internalmedicine.3477-19","journal-title":"Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/PHH.0000000000000822","article-title":"High completion rate for 12 weekly doses of isoniazid and rifapentine as treatment for latent Mycobacterium tuberculosis infection in the Federal Bureau of prisons","volume":"25","author":"Schmit KM","year":"2019","unstructured":"Schmit KM, Lobato MN, Lang SG, Wheeler S, Kendig NE, Bur S. High completion rate for 12 weekly doses of isoniazid and rifapentine as treatment for latent Mycobacterium tuberculosis infection in the Federal Bureau of prisons. J Public Health Manag Pract. 2019, 25:1-6. 10.1097\/PHH.0000000000000822","journal-title":"J Public Health Manag Pract"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.05.009","article-title":"Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-a prospective observational study in Taiwan","volume":"96","author":"Feng JY","year":"2020","unstructured":"Feng JY, Huang WC, Lin SM, et al.. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-a prospective observational study in Taiwan. Int J Infect Dis. 2020, 96:550-7. 10.1016\/j.ijid.2020.05.009","journal-title":"Int J Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222810","article-title":"Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: a multicentre cohort analysis","volume":"14","author":"Han SS","year":"2019","unstructured":"Han SS, Lee SJ, Yim JJ, Song JH, Lee EH, Kang YA. Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: a multicentre cohort analysis. PLoS One. 2019, 14:10.1371\/journal.pone.0222810","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-019-00240-1","article-title":"Latent tuberculosis treatment completion rates from prescription drug administrative data","volume":"110","author":"Plourde PJ","year":"2019","unstructured":"Plourde PJ, Basham CA, Derksen S, et al.. Latent tuberculosis treatment completion rates from prescription drug administrative data. Can J Public Health. 2019, 110:705-13. 10.17269\/s41997-019-00240-1","journal-title":"Can J Public Health"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3468-z","article-title":"Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study","volume":"18","author":"Schein YL","year":"2018","unstructured":"Schein YL, Madebo T, Andersen HE, et al.. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018, 18:587. 10.1186\/s12879-018-3468-z","journal-title":"BMC Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.17269\/cjph.104.3643","article-title":"Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010","volume":"104","author":"Rivest P","year":"2013","unstructured":"Rivest P, Street MC, Allard R. Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010. Can J Public Health. 2013, 104:235-9. 10.17269\/cjph.104.3643","journal-title":"Can J Public Health"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap R","year":"2017","unstructured":"Belknap R, Holland D, Feng PJ, et al.. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017, 167:689-97. 10.7326\/M17-1150","journal-title":"Ann Intern Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.9825","article-title":"Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study","volume":"20","author":"Lam CK","year":"2018","unstructured":"Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study. J Med Internet Res. 2018, 20:10.2196\/jmir.9825","journal-title":"J Med Internet Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6614a3","article-title":"Use of video directly observed therapy for treatment of latent tuberculosis infection - Johnson County, Kansas, 2015","volume":"66","author":"Holzschuh EL","year":"2017","unstructured":"Holzschuh EL, Province S, Johnson K, et al.. Use of video directly observed therapy for treatment of latent tuberculosis infection - Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep. 2017, 66:387-9. 10.15585\/mmwr.mm6614a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2017","article-title":"The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial","volume":"51","author":"Johnston JC","year":"2018","unstructured":"Johnston JC, van der Kop ML, Smillie K, et al.. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. Eur Respir J. 2018, 51:10.1183\/13993003.01488-2017","journal-title":"Eur Respir J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner D","year":"2017","unstructured":"Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017, 167:248-55. 10.7326\/M17-0609","journal-title":"Ann Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/22423982.2020.1758501","article-title":"The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study","volume":"79","author":"Alvarez GG","year":"2020","unstructured":"Alvarez GG, Van Dyk D, Mallick R, et al.. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. Int J Circumpolar Health. 2020, 79:10.1080\/22423982.2020.1758501","journal-title":"Int J Circumpolar Health"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling TR","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al.. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020, 69:1-11. 10.15585\/mmwr.rr6901a1","journal-title":"MMWR Recomm Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73475-use-of-isoniazid-monotherapy-in-comparison-to-rifamycin-based-regimen-for-the-treatment-of-patients-with-latent-tuberculosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:53Z","timestamp":1707507593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73475-use-of-isoniazid-monotherapy-in-comparison-to-rifamycin-based-regimen-for-the-treatment-of-patients-with-latent-tuberculosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.25083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}